机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, China.[3]Chengdu Basebio Company, China.[4]Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.[5]Ningbo Diagnostic Pathology Center, Ningbo, Zhejiang, China.[6]Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China.台州恩泽医疗中心台州医院[7]Department of Rehabilitation, West Kyushu University, Japan.[8]Department of Urology, Kyung Hee University, South Korea.[9]Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Prolyl 4-hydroxylase subunit beta (P4HB) can catalyze the formation, breakage and rearrangement of disulfide bonds through two thioredoxin domains, which is important for the maintenance of oxidizing environment in endoplasmic reticulum. Recently, P4HB has been demonstrated its oncogenic role of tumorigenesis and development in cancers. Therefore, we comprehensively deciphered P4HB in human cancer from various aspects, including pan-cancer analysis and narrative summary. We also provided some possible interacted molecules and the top 10 predicted drugs targeting P4HB to contribute to future research. We proposed that P4HB was a potential target and brought new therapeutic opportunities for cancer patients.
基金：
National Natural
Science Foundation of China (Grant Nos. 82170432),
programs from Science and Technology Department of
Sichuan Province (Grant Nos. 2020YFSY0024), Luzhou
City Science and Technology Bureau (grant number
2021LZXNYDJ10 and 2020LZXNYDJ14), Cooperation
Project between the Second People's Hospital of Deyang
and Southwest Medical University (2022DYEXNYD
002).
第一作者机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.[2]Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, China.[3]Chengdu Basebio Company, China.[*2]West China Hospital, Sichuan University, Chengdu, China.The Affiliated Hospital of Southwest Medical University, Luzhou, China.Chengdu Basebio Company, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.[2]Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, China.[3]Chengdu Basebio Company, China.[*1]West China Hospital, Sichuan University, Chengdu, China[*2]West China Hospital, Sichuan University, Chengdu, China.The Affiliated Hospital of Southwest Medical University, Luzhou, China.Chengdu Basebio Company, China.
推荐引用方式(GB/T 7714)：
Feng Dechao,Wang Jie,Li Dengxiong,et al.Targeting Prolyl 4-Hydroxylase Subunit Beta (P4HB) in Cancer: New Roads to Travel[J].AGING AND DISEASE.2023,doi:10.14336/AD.2023.1126.
APA：
Feng Dechao,Wang Jie,Li Dengxiong,Wu Ruicheng,Tuo Zhouting...&Wei Wuran.(2023).Targeting Prolyl 4-Hydroxylase Subunit Beta (P4HB) in Cancer: New Roads to Travel.AGING AND DISEASE,,
MLA：
Feng Dechao,et al."Targeting Prolyl 4-Hydroxylase Subunit Beta (P4HB) in Cancer: New Roads to Travel".AGING AND DISEASE .(2023)
